Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 3/20 | 0.78 |
| ▸ | HTR1A | P08908 | 8/20 | 0.74 |
| ▸ | HTR2A | P28223 | 8/20 | 0.68 |
| ▸ | HTR2C | P28335 | 5/20 | 0.68 |
| ▸ | HTR2B | P41595 | 4/20 | 0.68 |
| ▸ | HTR1D | P28221 | 4/20 | 0.65 |
| ▸ | HTR6 | P50406 | 3/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.65 |
| ▸ | HTR1B | P28222 | 3/20 | 0.65 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.65 |
| ▸ | HTR3B | O95264 | 2/20 | 0.65 |
| ▸ | HTR1E | P28566 | 2/20 | 0.65 |
| ▸ | HTR1F | P30939 | 2/20 | 0.65 |
| ▸ | HTR7 | P34969 | 2/20 | 0.65 |
| ▸ | HTR3A | P46098 | 2/20 | 0.65 |
| ▸ | HTR5A | P47898 | 2/20 | 0.65 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.65 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.65 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.65 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435343 | 1.00 | MPO (0.78) | MPOHTR1AHTR2AHTR2CHTR2B | |
| SCHEMBL2615142 | 0.88 | MPO (1.00) | MPOHTR1AHTR2AHTR2CHTR2B | |
| SCHEMBL29904417 | 0.88 | MPO (1.00) | MPOHTR1AHTR2AHTR2CHTR2B | |
| SCHEMBL2615141 | 0.88 | MPO (1.00) | MPOHTR1AHTR2AHTR2CHTR2B | |
| SCHEMBL24243684 | 0.87 | HTR2A (0.80) | MPOHTR1AHTR2AHTR2CHTR2B | |
| SCHEMBL30053108 | 0.87 | HTR2A (0.80) | MPOHTR1AHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL32677864 | 0.86 | MPO (0.97) | MPOHTR1AHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL32677865 | 0.86 | MPO (0.97) | MPOHTR1AHTR2AHTR2CHTR2B | |
| SCHEMBL29564678 | 0.85 | HTR1A (1.00) | MPOHTR1AHTR2AHTR2CHTR2B | |
| SCHEMBL25882269 | 0.84 | HTR1A (0.65) | MPOHTR1AHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12343337-B2 | Compounds for increasing neural plasticity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-01 | — | — | US | disclosed |
| US-12269818-B2 | Analogs of xanomeline | TERRAN BIOSCIENCES INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240368149-A1 | ANALOGS OF XANOMELINE | TERRAN BIOSCIENCES INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | disclosed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240000795-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. | 2024-01-04 | — | — | US | disclosed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023129976-A1 | SALT AND SOLID FORMS OF KETANSERIN | TERRAN BIOSCIENCES, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-11 | — | — | US | disclosed |
| US-20220143051-A1 | COMPOSITIONS AND METHODS OF USE COMPRISING SUBSTANCES WITH NEURAL PLASTICITY ACTIONS ADMINISTERED AT NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSAGES AND FORMULATIONS | Arbormentis LLC (US) | 2022-05-12 | — | — | US | disclosed |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000795-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | HTR2A, HTR1A, HTR2C | MPO 4400/4885HTR1A 2/4885HTR2A 1/4885 |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | TPH2, AANAT, HTR2C | MPO 2595/4885HTR1A 12/4885HTR2A 5/4885 |
| US-12343337-B2 | Compounds for increasing neural plasticity | PNMT, GAP43, SLC18A2 | MPO 4338/4885HTR1A 29/4885HTR2A 10/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | MPO 4493/4885HTR1A 1/4885HTR2A 2/4885 |
| US-20240368149-A1 | ANALOGS OF XANOMELINE | HTR5A, HTR3A, HTR3B | MPO 1316/4885HTR1A 5/4885HTR2A 6/4885 |
| US-12269818-B2 | Analogs of xanomeline | HTR5A, HTR3A, HTR3B | MPO 1316/4885HTR1A 5/4885HTR2A 6/4885 |
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | MPO 2595/4885HTR1A 12/4885HTR2A 5/4885 |
| US-20220143051-A1 | COMPOSITIONS AND METHODS OF USE COMPRISING SUBSTANCES WITH NEURAL PLASTICITY ACTIONS ADMINISTERED AT NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSAGES AND FORMULATIONS | HTR2A, GRIN2A, HTR1A | MPO 2251/4885HTR1A 3/4885HTR2A 1/4885 |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | MPO 2595/4885HTR1A 12/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.